TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: improvement in scalp hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of glomerular endotheliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: No-reflow phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitrite/nitrate (NOx(-)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Autonomic function (RR intervals and SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean pulmonary arterial pressure (PAP(mean))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in urinary 8‐hydroxy deoxoguanosine (8‐OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD RS‐IV HV total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BTLA expression in CD3(+) T cells and CD4(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement rate of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rate after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: duodenal ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean serum ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean weekly dose of iron dextran
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coefficient of variation for CHr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine transaminase score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: serum miR‐122 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of CBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving A1C <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of sustained EDSS score worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS score at the end of the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in T1 black hole volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: wrinkle severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient acceptability rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma Control Questionnaire score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS-score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-15 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of tumor necrosis factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of weight regain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craniovertebral angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C6 and C7 peak‐to‐peak amplitude of dermatomal somatosensory evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of active joints in patients with juvenile idiopathic arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Positive VZV‐IgG titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time of gastrointestinal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of IL-6, CRP, and TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: itching efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of L-dopa therapy long term motor complications (UPDRS part IV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Surgical Site Infection (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative CRB-free catheter survival at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rates at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall failure rates at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of staining lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Quit rates at 75 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program enrollment rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Uterine contractile activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma 13,14-dihydro-15-keto-prostaglandin F2 alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endocervical phospholipase A2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limits of agreements between technologists for MBF and MFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average time spent on motion correcting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CRPC-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cancer-specific survival (CSS)
Endpoint domain: Mortality/survival
Primary endpoint: Child asking behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home FV availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child FV intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-minute APGAR scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to the first HR communication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of initiation of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of administration of epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients ordering the care booklet
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Urinary calcium excretion 4 h after calcium dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-month graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Lumbar vertebral function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeated deliberate self-harm
Endpoint domain: Adverse events/effects
Primary endpoint: CD4 T-cell nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV DNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time between HIV diagnosis and cART initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apolipoprotein-B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: affective distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental cost-utility ratio (ICUR)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Complete response rate in the delayed phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of triflusal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-144 of triflusal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of triflusal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TGUG test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of difficulty in breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction of discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of being symptom-free at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in esophageal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of post-operative wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: mean serum β‐carotene concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of at least 10% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incident tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: stump volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in working memory-executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in objective memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in fine motor speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appetite sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in volitional competence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in total psychiatric symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wall motion values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual perfusion scores concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OI decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Protective efficacy of the vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Seroconversion rates for H2 and LA-1 strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AIDS information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AIDS communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AIDS knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GERD frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GERD severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GERD-HRQL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in proximal arm volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in general health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Work of Breathing (WOB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of RF in superficial veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prevalence of abnormal RF in femoropopliteal veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Outward flow in perforating veins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: survival free of combined cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients still working after 1 year
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean number of sick days after ICD implantation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: diagnostic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counter-regulatory glucagon secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Counter-regulatory growth hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mortality rates in the hospital
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rates in the ICU
Endpoint domain: Mortality/survival
Primary endpoint: peak norepinephrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: period on catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLN identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false negative rate
Endpoint domain: Adverse events/effects
Primary endpoint: Death, recurrent nonfatal myocardial infarction, or development of severe congestive heart failure or cardiogenic shock by 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Total Physical Activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Point prevalence abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative rate of first recurrence of HCC
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative rate of second recurrence of HCC
Endpoint domain: Mortality/survival
Primary endpoint: Child-Pugh classification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained antitumour activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Instrumented anteroposterior measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFR (Peak Flow Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: significant graft disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial natriuretic peptide (ANP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of the test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Days in health centre hospitals
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement in the sternum and manubrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in overall ADHD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in social functions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Acceptability of lifestyle programs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Implementation fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Dose delivered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: magnitude of the PSA response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: velocity of the PSA nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of PSA normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL total antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma lipid peroxidation biomarker F(2 alpha)-isoprostane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of diabetes remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lipid hydroperoxides (LPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: protein carbonyls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nitrotyrosine residues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total glutathione (GSH) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Superficial infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in rectal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder volume correlation with V50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose coverage (D98% and D95%) to the prostatic bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Inotropic/vasopressor requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asberg Side Effect Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Health-Related Quality of Life (HRQOL) improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reduction of watery rhinorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal Snellen acuity at 5.5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal grating acuity at 5.5 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No quantifiable acuity at 5.5 years among blind eyes at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary patency rates for PTA and stents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Physical Component Summary (PCS) score at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Semen analysis parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: nitric oxide metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Candida IgG concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean reduction in VAS scores at t30
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients feeling well enough to go home without further ED intervention at t30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: elimination of trichomonal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: reduction in genitourinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant-related irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Implant removal rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean MDR decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of VF locations reaching a PLR endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective drainage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comprehension of inferences from challenging listening passages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual‐spatial working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac output during submaximal exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Failure of assigned NRS mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol blood levels at extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: subjective response to amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global appearance scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life